Valirx Plc, an investment holding company, engages in the research and development of oncology therapeutics and diagnostics in the United Kingdom. The company principally offers VAL 101 that acts to shut down the Bcl-2 gene, a proto-oncogene. It develops human papilloma virus diagnostic products based on the Nucleosomics, a platform for non-invasive tests for early cancer diagnosis based on epigenetic signal changes associated with malignancy; and HyperGenomics, a platform for differential diagnostic and prognostic tests in cancer, as well as testing for personalized medicine. The company also develops GeneICE compounds, which treat various diseases by acting to shut down harmful genes and prevent their expression. Valirx Plc is based in London, the United Kingdom.